Compare Citius Pharmaceuticals Inc (CTXR) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Health Care Select Sector SPDR Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Health Care Select Sector SPDR Fund trades at $168.52. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | XLV | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | — |
52-Week High | $1.82 | $168.44 |
52-Week Low | $0.48 | $131.16 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
XLV, the Health Care Select Sector SPDR ETF, trades at $167.93, down 0.3% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad healthcare exposure with a low expense ratio of 0.08% and a trailing dividend yield of 1.6%, positioning it as a cost-effective defensive play amid market volatility. Recent news highlights strong sector inflows and defensive demand, with earnings from key holdings like UnitedHealth showing resilience despite Medicaid pressures.
The outlook for XLV is positive, supported by its defensive characteristics and institutional interest, though risks include regulatory pressures and sector-specific volatility. Investors may find value in its diversification and steady performance, but should monitor healthcare policy developments and earnings trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
